Please wait while we load the requested 10-Q report or click the link below:
Compelling preclinical data presented at the European Society of Gene and Cell Therapy Annual Congress demonstrates the potential for redosing in AAV-mediated gene therapy; announced strategic partnership with AskBio and expect to enter the clinic in 2020
COMPARE head-to-head trial of SEL-212 in chronic refractory gout expected to be fully enrolled by the end of 2019; confirmed FDA meeting in January 2020 regarding Phase 3 clinical development plan
Raised $5.7 million in net proceeds in a private placement with participation from the management team and board of directors
Strengthened management team with appointments of Alison D. Schecter, M.D. as Chief Medical Officer and Brad Dahms as Chief Financial Officer
Company to host conference call today at 8:30 AM ET
Compelling Preclinical Gene Therapy Data Presented at the European Society of Gene and Cell Therapy (ESGCT): Data from four preclinical studies were presented at the ESGCT Annual Congress in Barcelona, Spain. These studies highlight the ability of ImmTOR to address key challenges in gene therapy, specifically, the re-dosing limitations which stem from adaptive immune responses against the adeno-associated virus (AAV) capsid. These data demonstrate that ImmTOR enables repeat dosing and enhances first dose transgene expression up to four-fold compared to gene therapy with AAV vector alone. These conclusions support the advancement of the Company’s gene therapy pipeline, and Selecta looks forward to the clinical development of its
The following information was filed by Selecta Biosciences Inc (SELB) on Friday, November 8, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Selecta Biosciences Inc's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Selecta Biosciences Inc.